pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.34215/1609-1175-2026-1-83-86pmj-3085Research ArticleНАБЛЮДЕНИЯ ИЗ ПРАКТИКИPRACTICE OBSERVATIONSРефрактерный псориатический артрит: клинический случай успешной терапии рисанкизумабомRefractory psoriatic arthritis: A clinical case study of successful risankizumab therapyhttps://orcid.org/0009-0008-8503-6374СиненкоА. А.SinenkoA. A.

Синенко Андрей Анатольевич – к.м.н., доцент Института терапии и инструментальной диагностики ТГМУ.

690002, Владивосток, пр-т Острякова, 2

тел.: +7 (914) 670-33-54

Andrey A. Sinenko – Cand. Sci. Med.), Associate Professor of the Institute of Therapy and Instrumental Diagnostics of the Pacific Medical University.

2, Ostryakova ave., 690106, Vladivostok

tel.: +7 (914) 670-33-54

sinenko_aa@mail.ruЛупачН. М.LupachN. M.

Владивосток

Vladivostok

СюсинаО. И.SyusinaO. I.

Владивосток

Vladivostok

ЗиньковаЕ. A.ZinkovaE. A.

Владивосток

Vladivostok

Тихоокеанский государственный медицинский университет; Приморская краевая клиническая больница № 1РоссияPacific State Medical University; Primorsky Regional Clinical Hospital № 1Russian FederationПриморская краевая клиническая больница № 1РоссияPrimorsky Regional Clinical Hospital № 1Russian FederationДальневосточный федеральный университетРоссияFar Eastern Federal UniversityRussian Federation202601052026018386Copyright © Синенко А.А., Лупач Н.М., Сюсина О.И., Зинькова Е.A., 20262026Синенко А.А., Лупач Н.М., Сюсина О.И., Зинькова Е.A.Sinenko A.A., Lupach N.M., Syusina O.I., Zinkova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/3085

Представлен клинический случай псориатического артрита. Выполнена оценка эффективности ингибитора IL-23 рисанкизумаба (РИС) у пациента с высокоактивным ПсА, не отвечавшим на стандартную терапию. Показана высокая эффективность применения РИС, обеспечившая клиническую ремиссию кожных проявлений и значительное снижение активности артрита, подтверждающая важность биологической терапии и стратегии treat-to-target.

This article presents a clinical case of psoriatic arthritis (PsA). Its focus is on the efficacy of risankizumab (RIS), an IL-23 inhibitor, in treating a patient with highly active PsA who did not respond to standard therapy. It was demonstrated that RIS is highly effective through the clinical remission of skin manifestations and a significant reduction in arthritis activity. Thus, these results confirm the importance of biological therapy and the treat-to-target strategy.

псориатический артритГИБТрисанкизумабингибитор IL-23treat-to-targetpsoriatic arthritisgenetically engineered biological therapyrisankizumabIL-23 inhibitortreat-to-targetReferencesAzuaga AB, Ramírez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences. 2023;24(5):4901. doi: 10.3390/ijms24054901Azuaga AB, Ramírez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. International Journal of Molecular Sciences. 2023;24(5):4901. doi: 10.3390/ijms24054901Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692. doi: 10.1016/j.berh.2021.101692Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021;35(2):101692. doi: 10.1016/j.berh.2021.101692Хобейш М.М., Соколовский Е.В. Системная терапия псориаза и псориатического артрита: алгоритмы назначения. Вестник дерматологии и венерологии. 2025;101(1):28–49. doi: 10.25208/vdv16830Khobeysh MM, Sokolovskiy EV. Systemic therapy of psoriasis and psoriatic arthritis: assignment algorithms. Vestnik dermatologii i venerologii. 2025;101(1):28–49 (In Russ.). doi: 10.25208/vdv16830Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–822. doi: 10.1136/annrheumdis-2021-221664Mease PJ, Deodhar AA, van der Heijde D, Behrens F, Kivitz AJ, Neal J, Kim J, Singhal S, Nowak M, Banerjee S. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022;81(6):815–822. doi: 10.1136/annrheumdis-2021-221664Proft F, Lucas Ribeiro A, Singla S, Chandran V, Liao W, Lindsay C, Soriano ER, Bhutani T, Deodhar A, de Vlam K, Eder L, Kishimoto M, Leung YY, Lubrano E, McGonagle D, Poddubnyy D, Savage L, van den Bosch F, Mease PJ. Op0175Establishing Definitions For Difficult-To-Treat Psoriatic Arthritis (D2t-PsA) And Complex-To-Manage Psoriatic Arthritis (C2M-PsA): Insights from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (Grappa) Initiative. Annals of the Rheumatic Diseases. 2025;84(1):143–145. doi: 10.1016/j.ard.2025.05.188Proft F, Lucas Ribeiro A, Singla S, Chandran V, Liao W, Lindsay C, Soriano ER, Bhutani T, Deodhar A, de Vlam K, Eder L, Kishimoto M, Leung YY, Lubrano E, McGonagle D, Poddubnyy D, Savage L, van den Bosch F, Mease PJ. Op0175Establishing Definitions For Difficult-To-Treat Psoriatic Arthritis (D2t-PsA) And Complex-To-Manage Psoriatic Arthritis (C2M-PsA): Insights from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (Grappa) Initiative. Annals of the Rheumatic Diseases. 2025;84(1):143–145. doi: 10.1016/j.ard.2025.05.188Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Soliman AM, Eldred A, Barcomb L, Behrens F. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology. 2023;62(6):2113–2121. doi: 10.1093/rheumatology/keac607Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, Soliman AM, Eldred A, Barcomb L, Behrens F. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study. Rheumatology. 2023;62(6):2113–2121. doi: 10.1093/rheumatology/keac607

The authors declare that there are no conflicts of interest present.